$1.12
0.0%
Downside
Day's Volatility :2.61%
Upside
2.61%
43.75%
Downside
52 Weeks Volatility :88.5%
Upside
79.56%
Period | Flora Growth Corp | Sector (Consumer Staples) | Index (Russel 2000) |
---|---|---|---|
3 Months | -15.44% | 2.8% | 0.0% |
6 Months | -8.73% | 7.0% | 0.0% |
1 Year | -45.24% | 2.3% | 0.0% |
3 Years | -98.73% | 8.6% | -20.2% |
Market Capitalization | 15.2M |
Book Value | $0.35 |
Earnings Per Share (EPS) | -6.24 |
Wall Street Target Price | 5.5 |
Profit Margin | -75.6% |
Operating Margin TTM | -8.8% |
Return On Assets TTM | -12.42% |
Return On Equity TTM | -165.13% |
Revenue TTM | 74.8M |
Revenue Per Share TTM | 9.44 |
Quarterly Revenue Growth YOY | -6.7% |
Gross Profit TTM | 2.4M |
EBITDA | -8.4M |
Diluted Eps TTM | -6.24 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.3 |
EPS Estimate Next Year | -0.01 |
EPS Estimate Current Quarter | -0.22 |
EPS Estimate Next Quarter | -0.12 |
What analysts predicted
Upside of 391.07%
FY20 | Y/Y Change | |
---|---|---|
Revenue | 106.0K | - |
Net Income | -14.3M | ↑ 401.35% |
Net Profit Margin | -13.5K% | - |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 9.0M | ↑ 8371.7% |
Net Income | -21.4M | ↑ 49.81% |
Net Profit Margin | -237.87% | ↑ 13214.02% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 37.2M | ↑ 313.93% |
Net Income | -52.6M | ↑ 146.38% |
Net Profit Margin | -141.59% | ↑ 96.28% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 76.1M | ↑ 104.65% |
Net Income | -53.9M | ↑ 2.4% |
Net Profit Margin | -70.85% | ↑ 70.74% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 11.5M | ↑ 6.73% |
Net Income | -12.5M | ↑ 70.22% |
Net Profit Margin | -109.02% | ↓ 40.67% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 20.1M | ↑ 75.01% |
Net Income | -3.9M | ↓ 68.82% |
Net Profit Margin | -19.42% | ↑ 89.6% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 21.5M | ↑ 6.73% |
Net Income | -44.6M | ↑ 1041.0% |
Net Profit Margin | -207.62% | ↓ 188.2% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 17.3M | ↓ 19.31% |
Net Income | 1.2M | ↓ 102.78% |
Net Profit Margin | 7.14% | ↑ 214.76% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 18.0M | ↑ 3.8% |
Net Income | -8.3M | ↓ 769.77% |
Net Profit Margin | -46.09% | ↓ 53.23% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 18.0M | ↑ 0.31% |
Net Income | -3.4M | ↓ 59.28% |
Net Profit Margin | -18.71% | ↑ 27.38% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.2M | - |
Total Liabilities | 2.5M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 19.5M | ↑ 1558.49% |
Total Liabilities | 3.2M | ↑ 29.21% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 85.5M | ↑ 339.44% |
Total Liabilities | 8.5M | ↑ 166.65% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 81.0M | ↓ 5.26% |
Total Liabilities | 24.6M | ↑ 187.83% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 23.6M | ↓ 70.83% |
Total Liabilities | 17.2M | ↓ 29.92% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 81.0M | ↑ 10.74% |
Total Liabilities | 24.6M | ↑ 29.56% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 77.0M | ↓ 4.87% |
Total Liabilities | 23.4M | ↓ 4.67% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 30.5M | ↓ 60.44% |
Total Liabilities | 20.3M | ↓ 13.56% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 31.6M | ↑ 3.68% |
Total Liabilities | 18.5M | ↓ 8.76% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 23.6M | ↓ 25.23% |
Total Liabilities | 17.2M | ↓ 6.8% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 24.3M | ↑ 2.74% |
Total Liabilities | 21.1M | ↑ 22.73% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -453.8K | - |
Investing Cash Flow | -517.2K | - |
Financing Cash Flow | 1.0M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -8.4M | ↑ 1755.58% |
Investing Cash Flow | -2.2M | ↑ 318.41% |
Financing Cash Flow | 25.8M | ↑ 2469.62% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.6M | ↑ 145.2% |
Investing Cash Flow | -14.6M | ↑ 572.37% |
Financing Cash Flow | 58.1M | ↑ 125.08% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.1M | ↓ 37.21% |
Investing Cash Flow | -102.0K | ↓ 35.03% |
Financing Cash Flow | 5.3M | ↓ 1387.71% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.3M | ↑ 105.61% |
Investing Cash Flow | -102.0K | ↑ 0.0% |
Financing Cash Flow | -19.0K | ↓ 100.36% |
Sell
Neutral
Buy
Flora Growth Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Flora Growth Corp | 13.86% | -8.73% | -45.24% | -98.73% | -98.8% |
![]() Neurocrine Biosciences Inc. | 7.56% | 2.78% | 45.55% | 52.55% | 67.01% |
![]() Haleon Plc Spon Ads | 7.53% | 11.87% | 3.28% | 23.35% | 23.35% |
![]() Zoetis Inc. | 5.77% | -5.62% | -5.85% | -9.99% | 57.03% |
![]() Viatris Inc. | 12.75% | -1.42% | 12.21% | -15.03% | -28.03% |
![]() Catalent, Inc. | 4.08% | 11.91% | 19.53% | -48.27% | 2.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Flora Growth Corp | NA | NA | NA | -0.3 | -1.65 | -0.12 | NA | 0.35 |
![]() Neurocrine Biosciences Inc. | 39.75 | 39.75 | 0.44 | 3.99 | 0.18 | 0.1 | NA | 23.72 |
![]() Haleon Plc Spon Ads | 29.9 | 29.9 | 1.69 | 0.39 | 0.07 | 0.04 | 0.02 | 1.8 |
![]() Zoetis Inc. | 34.62 | 34.62 | 2.58 | 5.77 | 0.5 | 0.14 | 0.01 | 11.07 |
![]() Viatris Inc. | 224.4 | NA | 0.06 | 2.73 | 0.0 | 0.03 | 0.04 | 16.81 |
![]() Catalent, Inc. | 211.02 | NA | 2.06 | 0.2 | -0.28 | -0.01 | NA | 19.96 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Flora Growth Corp | Buy | $15.2M | -98.8% | NA | -75.6% |
![]() Neurocrine Biosciences Inc. | Buy | $14.7B | 67.01% | 39.75 | 18.65% |
![]() Haleon Plc Spon Ads | Buy | $41.0B | 23.35% | 29.9 | 9.64% |
![]() Zoetis Inc. | Buy | $82.0B | 57.03% | 34.62 | 27.38% |
![]() Viatris Inc. | Hold | $14.2B | -28.03% | 224.4 | -0.37% |
![]() Catalent, Inc. | Hold | $10.6B | 2.08% | 211.02 | -28.44% |
Insights on Flora Growth Corp
Revenue is up for the last 3 quarters, 17.31M → 18.03M (in $), with an average increase of 2.0% per quarter
Netprofit is up for the last 2 quarters, -8.28M → -3.37M (in $), with an average increase of 145.6% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 45.5% return, outperforming this stock by 90.7%
In the last 3 years, Neurocrine Biosciences Inc. has given 52.6% return, outperforming this stock by 151.3%
Amundi
Renaissance Technologies Corp
Bank of America Corp
Geode Capital Management, LLC
Vanguard Group Inc
HRT FINANCIAL LLC
at flora growth corp. (flora), we are building the world’s largest and lowest cost vertically-integrated producer of organic cannabis and pharmaceutical-grade medical products as well as cbd-based consumer products.
Organization | Flora Growth Corp |
Employees | 97 |
CEO | Mr. Clifford A. Starke |
Industry | Healthcare |